Novaliq is a German ophthaltmic pharmaceutical company. The company’s products are centred on its proprietary water-free technology, EyeSol® for topical ocular drug delivery. Novaliq is focused on developing the technology for use in treatments for dry eye disease.
Novaliq is the developer of the first water-free technology for ocular drug delivery. It is a specialist pharmaceutical formulation technology company that develops in-house topical ophthalmic formulations for dry eye disease based on its proprietary technology.
Novaliq’s product portfolio includes:
- CyclASol®, a preservative-free cyclosporine A solution for the treatment of moderate to severe dry eye disease. CyclASol® is evaluated in the Phase IIb/III ESSENCE study.
- NOV03, the first drug to treat evaporative dry eye disease associated with meibomian gland dysfunction. NOV03 is evaluated in the Phase II SEECASE study.
- NovaTears®, a preservative-free eye lubricant for tear film stabilisation in evaporative dry eye disease. NovaTears® is marketed under CE-approval in Australia and New Zealand by AFT Pharmaceuticals and as EvoTears® in Europe by Ursapharm.
Novaliq is based in Heidelberg, Germany, with a scientific office in Cambridge, MA, US. The long-term shareholder is dievini Hopp BioTech holding GmbH, a private equity and venture capital firm active in the health and life science sectors.